AI
KPTI icon

Analytic Investors’s Karyopharm Therapeutics KPTI Stock Holding History

Analytic Investors’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-589
Closed -$273K – 560
2014
Q1 		$273K Buy
+589
New +$299K ﹤0.01% 516

Other funds holding KPTI

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCMI
Foresite Capital Management I Larkspur, California $21.4M AUM 80.48% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Analytic Investors's KPTI Position: Q2 2014 in Review

Analytic Investors sold out of Karyopharm Therapeutics (KPTI) in Q2 2014, closing a stake of 589 shares — an estimated $273K sold.

Analytic Investors first reported a position in KPTI in Q1 2014 and held it in 1 quarter. The position peaked at $273K in Q1 2014. 78 funds tracked by Wall St. Rank hold KPTI as of Q2 2014.

  • Analytic Investors reported no remaining Karyopharm Therapeutics position as of Q2 2014 after selling out during the quarter.
  • Analytic Investors sold 589 Karyopharm Therapeutics shares in Q2 2014, an estimated $273K.
  • Analytic Investors first reported a position in Karyopharm Therapeutics in Q1 2014 and held it in 1 quarter.
  • Analytic Investors's Karyopharm Therapeutics position peaked at $273K in Q1 2014.
  • 78 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2014.

Based on Analytic Investors's 13F filing for Q2 2014, filed 13 Aug 2014.